Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OncoCyte Corp OCX

Healthcare Biotechnology
Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict... see more

Recent & Breaking News (NDAQ:OCX)

Oncocyte to Present New Data on DetermaIO(TM) from NeoTRIPaPDL1 Trial in Oral Presentation from Late-Breaking Abstract at ESMO 2021

GlobeNewswire September 13, 2021

Oncocyte to Participate in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference

GlobeNewswire September 7, 2021

Oncocyte Launches First Real-World Evidence (RWE) Registry to Evaluate Biomarker Impact on Early-Stage Lung Cancer Treatment Decisions and Outcomes

GlobeNewswire August 17, 2021

Oncocyte Reports Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 10, 2021

Oncocyte to Participate in Upcoming Investor Events

GlobeNewswire August 9, 2021

Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10

GlobeNewswire July 27, 2021

Oncocyte Celebrates Women Thoracic Surgeons in #ShesMySurgeon Campaign

GlobeNewswire June 22, 2021

EchelonDx and Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical Test Offerings

Business Wire June 15, 2021

Oncocyte Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocyte's DetermaIO Test in Colorectal Cancer, the Second Leading Cause of Cancer Mortality Globally

GlobeNewswire June 3, 2021

Oncocyte Selected as New "Day One" Launch Site for QIAGEN's Companion Diagnostics Test to Identify Patients for Amgen's Newly FDA-Approved Drug LUMAKRAS (Sotorasib) For Advanced Stage Lung Cancer

GlobeNewswire June 1, 2021

Oncocyte Reports First Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire May 17, 2021

Medicare Coverage Determination for Molecular Testing Announced for Solid Organ Allograft Rejection, Citing Multiple Publications from OncoCyte Corporation's Subsidiary Chronix Biomedical, Inc.

GlobeNewswire May 6, 2021

Oncocyte to Report First Quarter 2021 Financial Results on Monday, May 17

GlobeNewswire May 4, 2021

Oncocyte to Present New Data on DetermaIO(TM) Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the 2021 ASCO Annual Meeting

GlobeNewswire April 28, 2021

Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc.

GlobeNewswire April 19, 2021

Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors

GlobeNewswire April 14, 2021

Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO(TM)

GlobeNewswire April 10, 2021

Oncocyte to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference

GlobeNewswire April 6, 2021

Oncocyte Provides Corporate Update and Reports Fourth Quarter and Annual 2020 Financial Results

GlobeNewswire March 16, 2021

Oncocyte Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO(TM) to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types

GlobeNewswire March 16, 2021